<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05091476</url>
  </required_header>
  <id_info>
    <org_study_id>OC-1901AR</org_study_id>
    <nct_id>NCT05091476</nct_id>
  </id_info>
  <brief_title>OcuDyne System in the Treatment of AMD</brief_title>
  <official_title>A Clinical Study to Evaluate the Safety and Feasibility of the OcuDyne System in the Treatment of Age-Related Macular Degeneration (AMD)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OcuDyne, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>OcuDyne, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>Yes</is_unapproved_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the safety and feasibility of using the OcuDyne OPTiC System in patients&#xD;
      with late-stage non-exudative age-related macular degeneration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 15, 2021</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety</measure>
    <time_frame>Intraoperative through Week 4 postoperative</time_frame>
    <description>Procedural Complications &amp; Adverse Events</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Age-Related Macular Degeneration</condition>
  <arm_group>
    <arm_group_label>Eyes treated with the OPTiC System</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eyes that OPTiC System treatment has been completed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fellow Eye</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Contralateral comparator</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>OPTiC System</intervention_name>
    <description>OPTiC System procedure</description>
    <arm_group_label>Eyes treated with the OPTiC System</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Must be able to understand and provide informed consent on an Independent Ethics&#xD;
             Committee (EC) approved informed consent form (ICF)&#xD;
&#xD;
          2. Must be willing and able to return for scheduled treatment and follow-up examinations&#xD;
             for up to a 7-month duration&#xD;
&#xD;
          3. Adults at least 60 years of age at the time of consent&#xD;
&#xD;
          4. Diagnosed with non-exudative Age-Related Macular Degeneration with current or previous&#xD;
             evidence of at least one large drusen (measuring 125 microns or greater) and nascent&#xD;
             geographic atrophy (nGA) or GA in the study eye&#xD;
&#xD;
          5. ETDRS BCVA letter score of less than 56 letters (Snellen equivalent of 20/80 or worse)&#xD;
             in the study eye, which in the Investigator's judgment is caused by non-exudative AMD&#xD;
&#xD;
          6. The confirmed presence of OA stenosis (leading to the study eye).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        OCULAR&#xD;
&#xD;
          1. Any surgical intraocular treatment (including laser) within 3 months in the study eye.&#xD;
&#xD;
          2. History of exudative AMD or Anti-Vascular Endothelial Growth Factor (anti-VEGF)&#xD;
             injections within 6 months in the study eye.&#xD;
&#xD;
          3. Presence of ocular media affecting visual acuity or the ability to visualize the&#xD;
             retina in either eye (e.g., central corneal scarring, lens opacities along visual&#xD;
             axis, posterior capsule opacification, etc.).&#xD;
&#xD;
          4. History of chronic, recurring inflammatory eye disease in either eye (e.g., scleritis,&#xD;
             uveitis, corneal edema, etc.)&#xD;
&#xD;
          5. Presence of diabetic retinopathy in either eye.&#xD;
&#xD;
          6. Evidence of macular edema secondary to exudation in the study eye.&#xD;
&#xD;
          7. History of amaurosis fugax, central or retinal artery or vein occlusion, anterior&#xD;
             ischemic optic neuropathy (AION) or non-arteritic anterior ischemic optic neuropathy&#xD;
             (NAION) or any diagnosis of a macular disease other than AMD such as Stargardt&#xD;
             disease, cone rod dystrophy, angioid streaks, or toxic maculopathies such as Plaquenil&#xD;
             maculopathy.&#xD;
&#xD;
          8. Myopia &gt; 6.0 Diopters (D) spherical equivalent (SE) or Axial Length â‰¥ 26.0 mm in the&#xD;
             study eye.&#xD;
&#xD;
          9. Presence of visually significant epiretinal membrane in the study eye.&#xD;
&#xD;
         10. Participation in any eye-related drug or device clinical trial involving either eye&#xD;
             within 90 days prior to enrolling in this study and/or during study participation.&#xD;
&#xD;
             Non-Ocular&#xD;
&#xD;
         11. Any condition that prohibits the use of intravenous contrast agents (e.g., renal&#xD;
             insufficiency, previous anaphylactoid reaction to contrast material, treatment with&#xD;
             nephrotoxic agents, etc.).&#xD;
&#xD;
         12. Previous stroke, including ischemic, hemorrhagic or transient ischemic attack (TIA).&#xD;
&#xD;
         13. Previous myocardial infarction (MI), including ST segment elevation (STEMI), non-ST&#xD;
             segment elevation (NSTEMI) or coronary spasm/angina.&#xD;
&#xD;
         14. Coronary or other intravascular percutaneous procedure, including balloon angioplasty,&#xD;
             stent or filter placement within the last 6 months.&#xD;
&#xD;
         15. Complete occlusion of the ophthalmic artery.&#xD;
&#xD;
         16. Pacemaker, Cochlear, or neurostimulation implant.&#xD;
&#xD;
         17. Presence of cranial aneurysm, clinically significant stenosis in common carotid artery&#xD;
             or internal carotid artery, or tortuous vascular anatomy as seen on pre-procedural CT&#xD;
             Angiogram that, in the clinical judgement of the investigator, represents an&#xD;
             unreasonable risk to perform the intervention.&#xD;
&#xD;
         18. Condition associated with increased bleeding risk including but not limited to: major&#xD;
             surgical procedure or trauma within 30 days of screening; clinically significant&#xD;
             gastrointestinal bleeding within 1 year of screening; known gastric or duodenal ulcer;&#xD;
             history of intracranial or spinal bleeding; chronic hemorrhagic disorder; treatment&#xD;
             with oral anticoagulant medications (e.g., Warfarin / non-vitamin K anticoagulants&#xD;
             [NOACs] exclusionary; aspirin or clopidogrel allowed), known intracranial neoplasm,&#xD;
             arteriovenous malformation, or aneurysm.&#xD;
&#xD;
         19. Treatment with oral anticoagulant medications (e.g., Warfarin / non-vitamin K&#xD;
             anticoagulants [NOACs] exclusionary; aspirin or clopidogrel allowed).&#xD;
&#xD;
         20. Sustained and uncontrolled hypertension with systolic blood pressure &gt; 180 mmHg.&#xD;
&#xD;
         21. Diagnosis of moderate to severe symptomatic congestive heart failure (CHF) or chronic&#xD;
             obstructive pulmonary disease (COPD)&#xD;
&#xD;
         22. Diagnosis of connective tissue, demyelinating, autoimmune, or inflammatory diseases&#xD;
             (e.g., lupus, rheumatoid arthritis, scleroderma, giant cell arteritis, multiple&#xD;
             sclerosis, etc.).&#xD;
&#xD;
         23. Intolerance of either pre- or post- procedure medication regimen.&#xD;
&#xD;
         24. Pregnancy, lactation, or plans to become pregnant during participation in this&#xD;
             clinical trial.&#xD;
&#xD;
         25. Participation in any other non-eye related drug or device clinical trial within 30&#xD;
             days prior to enrolling in this study and/or during study participation.&#xD;
&#xD;
             Other&#xD;
&#xD;
         26. Use of facial fillers or paralytic drugs during study participation.&#xD;
&#xD;
         27. Subject who, in the clinical judgement of the investigator, is not otherwise suitable&#xD;
             for participation in the study for another clinical reason, as documented by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Luana R Wilbur, BS</last_name>
    <phone>858-442-7178</phone>
    <email>lwilbur@ocudyne.com</email>
  </overall_contact>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 12, 2021</study_first_submitted>
  <study_first_submitted_qc>October 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 25, 2021</study_first_posted>
  <last_update_submitted>October 12, 2021</last_update_submitted>
  <last_update_submitted_qc>October 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Degeneration</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

